Drug Trial Radar · NCT07092215
Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jun 17, 2025
Primary completion
Jul 11, 2025
Study completion Jul 11, 2025
Sponsor
- Lead sponsor
- Stefan HeberAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main goal of this double-blind, randomized, placebo-controlled crossover study is to understand the molecular mechanisms of inflammation-induced increased pain sensitivity (hyperalgesia). These mechanisms are studied using a recently established human model of skin inflammation that mimics aspects of skin infection. A localized inflammatory response in the skin of healthy volunteers is elicited by locally injecting a small, safe dose of Lipopolysaccharide (LPS), a major component of gram-negative bacteria. The study addresses three key research questions: * Role of RAGE: To investigate if certain inflammatory effects of LPS, which contribute to hyperalgesia, are mediated by a signaling pathway involving the RAGE receptor. * Pain Sensitization: To examine how skin inflammation affects pain caused by acidic stimuli, and to differentiate this from purely mechanical pain. * Role of TRPV1: To determine if the contribution of the TRPV1 ion channel to acid-induced pain is different in inflamed skin. Participants will undergo an experimental session 4.5 hours after LPS injection to measure skin blood flow (using laser speckle imaging), mechanical pain sensitivity (using specialized tweezers), and pain induced by injecting a solution, of which the pH is gradually decreasing (acid-induced pain). The study has minimal risks due to the small, safe doses of substances used ('microdosing') and aims to lay the groundwork for developing new treatments for inflammatory pain conditions.
Conditions
- Pain
Interventions
Synthetic interstitial fluid (SIF) / SIF neutral pHDrug
Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
Synthetic interstitial fluid (SIF) / SIF acidic pHDrug
Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µMDrug
Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
LPS 5 ng / SIF neutral pHDrug
Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
LPS 5 ng / SIF acidic pHDrug
Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
LPS 5 ng / SIF acidic pH + BCTC 1 µMDrug
Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
LPS 5 ng + Azeliragon 100 µM / SIF neutral pHDrug
Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
LPS 5 ng + Azeliragon 100 µM / SIF acidic pHDrug
Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to 5.7)
LPS 5 ng + Resatorvid 10 µM / SIF neutral pHDrug
Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
LPS 5 ng + Resatorvid 10 µM / SIF acidic pHDrug
Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4 to pH 5.7)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Skin PerfusionTime frame: 4.5h after the (non-)LPS injections
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, State of Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.